New immune cell therapy for AML with NPM1 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests a new kind of immune cell therapy (called BSB-2002) for people with a specific type of AML that has returned or not responded to standard treatment. The therapy is made from your own white blood cells, given after a short course of chemotherapy to prepare your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your AML has come back after treatment or did not fully respond to at least two lines of therapy.
- Your blood or bone marrow has a specific NPM1 gene change (type A, D, G, or H).
- You have a certain immune marker called HLA-A*02:01 on your white blood cells.
- You are generally well enough to manage daily activities (ECOG 0-2) and have adequate organ function (kidney, liver, heart, lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.